Genfit SA took a significant step into its post-non-alcoholic steatohepatitis (NASH) future on 19 September, announcing that it will acquire privately held Versantis AG in a deal enabling it to develop potentially two mid-stage clinical candidates in acute-on-chronic liver failure (ACLF), an unmet medical need with high mortality.
Genfit To Pick Up Second Liver Failure Candidate In €40m Versantis Buyout
Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.
More from Deals
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.